Literature DB >> 9783675

Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?

S Mathison1, R Nagilla, U B Kompella.   

Abstract

During this century, several investigators reported that certain viruses, metals, drugs, and other solutes could bypass systemic circulation and enter the brain and/or cerebrospinal fluid directly following nasal administration. Although evidence clearly suggests that the olfactory epithelium and its olfactory cells play a major role, little is known about the mechanisms of direct transport of solutes into the brain. An overview of what is known about these mechanisms may aid in further research in this field, including studies of direct drug delivery to the central nervous system. This review, in addition to summarizing the literature to date, clearly describes the intricate association of the anatomical features involved in direct entry of solutes into the brain following nasal administration. To aid in the understanding of the possible routes a solute can take after nasal administration, the anatomy of the olfactory epithelium and surrounding tissues is described, and a detailed scheme delineating the emerging pathways is presented. Techniques used in delineating these pathways and studies supporting a particular pathway are discussed in greater detail. Finally, some factors influencing the direct transport of solutes to the cerebrospinal fluid and brain are summarized.

Mesh:

Year:  1998        PMID: 9783675     DOI: 10.3109/10611869808997870

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  30 in total

1.  Nose-to-brain transport pathways of wheat germ agglutinin conjugated PEG-PLA nanoparticles.

Authors:  Qingfeng Liu; Yehong Shen; Jie Chen; Xiaoling Gao; Chengcheng Feng; Lu Wang; Qizhi Zhang; Xinguo Jiang
Journal:  Pharm Res       Date:  2011-12-14       Impact factor: 4.200

2.  Airflow and nanoparticle deposition in rat nose under various breathing and sniffing conditions: a computational evaluation of the unsteady effect.

Authors:  Jianbo Jiang; Kai Zhao
Journal:  J Aerosol Sci       Date:  2010-11-01       Impact factor: 3.433

Review 3.  The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.

Authors:  D S Quintana; A J Guastella; L T Westlye; O A Andreassen
Journal:  Mol Psychiatry       Date:  2015-11-10       Impact factor: 15.992

4.  First Steps to Develop and Validate a CFPD Model in Order to Support the Design of Nose-to-Brain Delivered Biopharmaceuticals.

Authors:  Lucas Engelhardt; Martina Röhm; Chrystelle Mavoungou; Katharina Schindowski; Annette Schafmeister; Ulrich Simon
Journal:  Pharm Res       Date:  2016-02-17       Impact factor: 4.200

5.  Intranasal drug delivery: a novel approach.

Authors:  Yashpal Chugh; Pragati Kapoor; A K Kapoor
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2009-04-25

6.  Delivery of cefotaxime to the brain via intranasal administration.

Authors:  Prashanth Manda; Jamie K Hargett; Siva Ram Kiran Vaka; Michael A Repka; S Narasimha Murthy
Journal:  Drug Dev Ind Pharm       Date:  2011-06-27       Impact factor: 3.225

Review 7.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Direct nose-to-brain transfer of morphine after nasal administration to rats.

Authors:  Ulrika Espefält Westin; Emma Boström; Johan Gråsjö; Margareta Hammarlund-Udenaes; Erik Björk
Journal:  Pharm Res       Date:  2006-02-25       Impact factor: 4.200

9.  P-Glycoprotein attenuates brain uptake of substrates after nasal instillation.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

10.  Strategies for enhanced drug delivery to the central nervous system.

Authors:  V S N M Dwibhashyam; A N Nagappa
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.